 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Tandem Diabetes Care (TNDM) designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States.
The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump's software.
In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and various pump accessories.
Its products in development include t:slim X2 with control IQ technology; t:sport insulin delivery system; and connected (mobile) health offerings.
The Company is scheduled to report its earnings on February 24th. Ahead of that shares have formed a bullish "wedge" and are expected to move higher. On November 4th, 2019, TNDM reported a 3rd Quarter September 2019 loss of $0.13 per share on revenue of $94.7 million. The consensus estimate was a loss of $0.20 per share on revenue of $88.5 million. Revenue grew 104.6% on a year-over-year basis.
The company said it expects 2019 revenue of $358.0 million to $365.0 million. The company's previous guidance was revenue of $350.0 million to $365.0 million and the current consensus estimate is revenue of $359.3 million for the year ending December 31, 2019.
Entry Point: $75.00
Stop Loss: $71.00
Trading Range: $40.46 - $78.75
Target Price: $82.50
TNDM closed at $82.60
